Mental Health Therapeutics: Is Psilocybin the Next Market Disruptor?

Silhouette of a head with a networked brain containing a pill, set against a backdrop of rising bar graphs, symbolizing mental enhancement and growth.
April 14 , 2026  |  By Ashutosh Bhave

Share this via:

Who is this research for? This research is relevant for healthcare executives, mental health providers, and investors evaluating opportunities and risks in the emerging psychedelic therapeutics market.

Executive Summary

This research from Ashutosh Bhave at the Sam M. Walton College of Business (Department of Marketing) examines how psilocybin reforms are associated with changes in psychedelic usage patterns, a potential indicator of shifting demand within the psychedelic therapeutics industry. Using individual-level panel data from the University of Michigan’s Monitoring the Future study, the analysis compares reported use of psilocybin, LSD and MDMA before and after milestones such as Oregon’s 2020 legalization of supervised psilocybin services.

The findings suggest that psilocybin reforms are associated with an increase in psilocybin use and a corresponding decline in MDMA use (and, in some states, LSD use). For healthcare executives and investors, this pattern suggests policy reform may position psilocybin as the central compound within the $70 billion mental health therapeutics market in a trajectory that increasingly resembles that of cannabis reform.

Action Items for Industry

  • Align infrastructure with regulatory intent: Develop facilitator training, clinical oversight, and compliance systems that reflect state-supervised therapeutic models rather than retail cannabis frameworks.
  • Differentiate through safety and legitimacy: Emphasize psilocybin’s comparatively lower risk profile and collaborate with mental health professionals and patient advocates to build credibility and public trust.
  • Address pricing and access barriers: Assess whether high per-session costs, limited reimbursement pathways, or equity concerns could constrain adoption or encourage parallel gray markets.
  • Prepare for uneven policy adoption: Build adaptable operating and investment strategies that can function across a patchwork of state and municipal regulations.

Quote from the Researcher

“We must engage with psilocybin now, balancing immediate action with careful research.”

– Ashutosh Bhave

Published in Journal of Public Policy & Marketing, available here.

📩 Interested in learning more? If you’d like additional information about this research or to connect directly with the researchers, please email us at research@walton.uark.edu.

Ashutosh BhaveDr. Ashutosh Bhave is assistant professor of marketing in the Sam M. Walton College of Business at the University of Arkansas. He received his PhD in Quantitative Marketing and his MS in Information Technology and Management from UT Dallas. He quantifies the causal impact of policy changes using econometrics and machine learning on quasi-experimental data. His research spans different areas, including the impact of free shipping programs in online retailing, brand conflicts on social media and their offline sales repercussions, and the influence of marijuana legalization on cigarette sales.